SeraCare Life Sciences has launched what it claims to be the first commercially available anti-dengue mixed titer performance panel. This addition to the company’s line of infectious disease panels responds to growing demand for accurate testing for dengue virus, which infects an estimated 50 to 100 million people annually, according to the World Health Organization.
The performance panel is designed to help blood-donor collection facilities, diagnostics manufacturers and clinical laboratories evaluate and troubleshoot their anti-dengue virus assays. It is derived from undiluted, unpreserved human plasma specimens, with 21 members representing a wide range of reactivity for anti-dengue IgM and IgG antibodies, from negative to strongly positive. Panel members include samples from individuals with recent and past infection by all four dengue viruses (DENV-1 through DENV-4).
Phone: 07 3386 7999
ALA Scientific Instruments RuFus cell unroofing system for plasma membrane isolation
ALA Scientific Instruments offers RuFus, a complete and user-friendly system for performing cell...
Lonza plateable mouse hepatocytes
Lonza provides plateable mouse hepatocytes from the four most common research mouse strains,...
PEPperPRINT cLIFT peptide microarray platform
At the core of the technology is a laser-based transfer process that is designed to deposit amino...
